Evidence map›Paper›PMID 39911857›Full record

ArticlePsychology research and behavior management2025

Coupling Bio-Resonance Neurotechnology (BRNT) and Dual Hemispheric Repetitive Transcranial Magnetic Stimulation (rTMS) Reduces Comorbid Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) as Demonstrated by PHQ-9 and GAD-7: Pilot Case Series.

Keerthy Sunder, Milan T Makale, Miles Makale, Jothsna Bodhanapati, Kevin T Murphy, Catherine A Dennen, David Baron, Panayotis K Thanos, Colin Hanna, John Wesson Ashford and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychology research and behavior management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Keerthy Sunder *Department of Psychiatry, University California, UC Riverside School of Medicine, Riverside, CA, USA.
Milan T Makale *Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, USA.
Miles Makale *Department of Psychology, University of California San Diego, San Diego, CA, USA.
Jothsna Bodhanapati *Division of Neuromodulation Research, Karma Doctors & Karma TMS, Palm Springs, CA, USA.
Kevin T Murphy *PeakLogic Inc., Del Mar, CA, USA.
Catherine A Dennen *Department of Family Medicine, Jefferson Health Northeast, Philadelphia, PA, USA.
David Baron *Division of Addiction Research & Education, Center for Sports, Exercise and Mental Health, Western University Health Sciences, Pomona, CA, USA.
Panayotis K Thanos *Behavioral Neuropharmacology and Neuroimaging Laboratory On Addictions (BNNLA), Research Institute On Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
Colin Hanna *Behavioral Neuropharmacology and Neuroimaging Laboratory On Addictions (BNNLA), Research Institute On Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
John Wesson Ashford *Stanford University, Psychiatric /Public Mental Health & Population Sciences Palo Alto, Stanford, CA, USA.
Kai-Uwe Lewandrowski *Department of Orthopaedics, Fundación Universitaria Sanitas, Bogotá D.C., Colombia.ORCID 0000-0001-7842-2914
Kenneth Blum *Sunder Foundation, Palm Springs, CA, USA.ORCID 0000-0001-6727-803X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) are prevalent comorbidities related to a greater likelihood of poor treatment outcomes and prolonged treatment for Reward Deficiency Syndrome (RDS) behaviors. The current exploratory case study of a small cohort (n=3; f=2 m=1) used novel neurotechnology to treat co-occurring MDD and GAD with a multifaceted intervention that combines the novel bio-resonance neurotechnology (BRNT) referred to as NuCalm

Indexed as

novel bio-résonance neurotechnologyparasympathetic and sympathetic nervous systemsRDSrepetitive transcranial magnetic stimulation(rTMS)reward deficiency syndrome(RDS)rTMS

Identifiers

PMID39911857
PMCPMC11796452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.